Drug Profile


Alternative Names: ORG 39479; PH-80; PH80-PMD; PH80-PMD NS

Latest Information Update: 17 Jun 2015

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Pherin Pharmaceuticals
  • Developer Pherin Pharmaceuticals; University of Pennsylvania
  • Class
  • Mechanism of Action Neurotransmitter receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Premenstrual syndrome

Most Recent Events

  • 17 Jun 2015 PH80 PMD is still in phase-II development for Premenstrual syndrome in USA
  • 27 Dec 2006 Results from a phase II trial in patients with Premenstrual syndrome have been added to the adverse events and Women's Health therapeutic trials sections
  • 18 Nov 1998 Phase-I clinical trials for Premenstrual syndrome in USA (Intranasal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top